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Abstract
Ischemic heart disease is the leading cause of death in India, and there are likely more myocardial 
infarctions in India than in any other country in the world. We have previously reported 
heterogeneous care for patients with myocardial infarction in Kerala, a state in southern India, 
including both gaps in optimal care and inappropriate care. Based on that prior work, limitations 
from previous non-randomized quality improvement studies, and promising gains in process of 
care measures demonstrated from previous randomized trials, we and the Cardiological Society of 
India – Kerala chapter sought to develop, implement, and evaluate a quality improvement 
intervention to improve process of care measures and clinical outcomes for these patients. In this 
paper, we report the rationale and study design for the Acute Coronary Syndrome Quality 
Improvement in Kerala (ACS QUIK) cluster randomized stepped wedge clinical trial 
(NCT02256657) in which we aim to enroll 15,750 participants with acute coronary syndromes 
across 63 hospitals. To date, the majority of participants are men (76%) and has ST-segment 
Corresponding author: Mark D. Huffman, MD, MPH, Department of Preventive Medicine, Northwestern University Feinberg School 
of Medicine, Chicago, IL 60611 USA, m-huffman@northwestern.edu, T: +1-312-503-5513, F: +1-312-908-9588. 
This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing 
this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it 
is published in its final citable form. Please note that during the production process errors may be discovered which could affect the 
content, and all legal disclaimers that apply to the journal pertain.
Operations Committee: Dr. Mark Huffman, Dr. PP Mohanan, Ms. Abigail Baldridge, Ms. Raji Devarajan, Dr. Dimple Kondal, Dr. 
Lihui Zhao, Mr. Mumtaj Ali, Mr. Prasad Arumugan, Mr. Divin Davies, Mr. Aneesh T.C., Dr. Dorairaj Prabhakaran, Dr. Donald M. 
Lloyd-Jones
Cardiological Society of India – Kerala chapter Steering Committee: Drs. Rajan Joseph Manjooran, Ashokan Nambiar, 
Sivasubramonian Sivasankaran, G. Vijayragahvan, Geevar Zachariah.
International Steering Committee: Drs. Dorairaj Prabhakaran (co-chair), Donald M. Lloyd-Jones (co-chair), K. Srinath Reddy, 
Robert O. Bonow, Darwin R. Labarthe, and Sidney C. Smith, Jr.
Data and Safety Monitoring Board: Drs. Brahmajee Nallamothu (chair), Thomas Alexander, Karla Hemming, Simon Thom, K.R. 
Sundaram. National Heart, Lung, and Blood Institute representative: Lawton Cooper.
HHS Public Access
Author manuscript
Am Heart J. Author manuscript; available in PMC 2018 March 01.
Published in final edited form as:
Am Heart J. 2017 March ; 185: 154–160. doi:10.1016/j.ahj.2016.10.026.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
elevation myocardial infarction (63%). The primary outcome is 30-day major adverse 
cardiovascular events defined as death, recurrent infarction, stroke, or major bleeding. Our 
secondary outcomes include health-related quality of life and individual- and household-level 
costs. We also describe the principal features and limitations of the stepped wedge study design, 
which may be important for other investigators or sponsors considering cluster randomized 
stepped wedge trials.
Keywords
acute coronary syndrome; quality improvement; stepped wedge trial
Background
Ischemic heart disease (IHD) is the leading cause of death in India.(1) There are likely more 
myocardial infarctions in India than in any other country in the world, due to the 
combination of a large population and relatively high disease burden.(2,3) We have 
previously reported data on the heterogeneous presentation, management, and outcomes 
among 25,748 patients with acute coronary syndromes (ACS) from 2007 to 2009 across 125 
hospitals that were part of the Kerala Acute Coronary Syndrome Registry.(4) Our findings 
demonstrated gaps in optimal medical care during hospitalization and at the time of 
discharge.(5) For example, while in-hospital antiplatelet use was >90%, in-hospital use of 
anticoagulants, beta-blockers, ACE-inhibitors, and statins was 70% or less for each 
medication. We also demonstrated examples of acute coronary syndrome management that 
was contraindicated according to clinical practice guidelines, including use of thrombolytics 
among 19% of patients with non-ST-segment myocardial infarction, which was associated 
with increased odds of in-hospital mortality (OR = 1.33 [95% CI 0.92, 1.91]) and major 
adverse cardiovascular events (OR = 1.63 [95% CI 1.19, 2.23]).(4)
Adherence to guideline-based therapies has been associated with improved in-hospital, 30-
day and 1-year clinical outcomes in acute coronary syndrome patients in multiple studies 
performed in the United States and other high-income countries. For example, the 
CRUSADE investigators demonstrated a 2.2% absolute difference in in-hospital mortality 
between the highest and lowest quartiles of adherence to acute coronary syndrome 
guidelines.(6) However, reported associations between guideline-based adherence and 
outcomes may not necessarily be causal because of potential confounding at the patient, 
clinician, or hospital levels. To overcome this potential limitation, investigators from 
Brazil(7) and China(8) have performed cluster randomized trials of acute coronary 
syndrome quality improvement interventions. Both previously reported trials demonstrated 
improvements in process measures but neither has been powered for nor has demonstrated 
improvements in outcomes. One large, ongoing trial in China (target N=25,000), the Clinical 
Pathways in Acute Coronary Syndrome – 3 (CPACS 3), is powered to detect a difference in 
clinical outcomes.(9)
Similar large-scale cluster randomized trials have not been carried out in India, a research 
gap at odds with the burden of disease. One pilot investigation in Kerala showed potential 
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benefits from the implementation of community and clinician education coupled with a 
health system intervention aimed to standardize treatment(10) and another pre/post study of 
pre-hospital health system improvement is ongoing in Karnataka.(11) Therefore, based on 
results from the Kerala Acute Coronary Syndrome Registry, limitations from previous non-
randomized studies, and promising gains demonstrated from previous randomized trials, we 
and the Cardiological Society of India – Kerala chapter sought to develop, implement, and 
evaluate a quality improvement intervention to improve process of care measures and 
clinical outcomes for patients with ACS in Kerala through our cluster randomized, stepped 
wedge Acute Coronary Syndrome Quality Improvement in Kerala (ACS QUIK) trial.
Methods
The methods described are based on the Standardized Reporting Items: Recommendations 
for Intervention Trials (SPIRIT) statement and checklist.(12) The cluster randomized 
stepped wedge design of ACS QUIK meant that the 63 participating hospitals (clusters) were 
randomized to one of five pre-defined steps for implementation of the intervention at study 
initiation in November 2014. Only the study biostatisticians knew the allocation schedule. 
After a four-month baseline period, the quality improvement toolkit was implemented 
among the hospitals randomized to step 1 (cohort 1, Figure 1). Through a one-way 
crossover design, hospitals in cohort 1 use the quality improvement toolkit through the end 
of the trial. Cohorts 2 through 5 implemented the quality improvement toolkit at months 8, 
12, 16 and 20, respectively, and use the toolkits from that time forward to the end of the 
study in November 2016.
Participants
Prior to study initiation, we invited hospitals that participated in the Kerala Acute Coronary 
Syndrome Registry to participate in ACS QUIK. To diversify our sample, we invited 
government hospitals, including government medical colleges, and hospitals with and 
without cardiac catheterization laboratories and those with and without cardiologists to 
participate. To be eligible, hospitals had to identify a principal investigator and either junior 
physician or nurse who would serve as a quality improvement champion for the trial.
Patients were eligible for inclusion if they presented with acute myocardial infarction and 
met at least 2 out of 3 criteria for myocardial infarction (chest pain, ST segment elevation on 
electrocardiography, and cardiac biomarker elevation greater than 3 times the upper limit of 
normal) consistent with the 3rd universal definition of myocardial infarction.(13) We chose 
to exclude patients with unstable angina because of the low event rate associated with this 
presentation, which would reduce our statistical power to demonstrate a difference with the 
study intervention. Informed consent in the local language, Malayalam, was obtained from 
eligible patients at admission and follow-up was conducted at 30-days post discharge.
We collected data based on the American College of Cardiology/American Heart 
Association’s Key Data Elements and Definitions for Measuring the Clinical Management 
and Outcomes Key of Patients With Acute Coronary Syndromes and Coronary Artery 
Disease.(14) Data included, but were not limited to socio-demographics, presenting signs 
and symptoms, medical history, laboratory studies (e.g., cardiac biomarkers, serum 
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creatinine, hemoglobin), diagnostic studies (e.g., electrocardiography, echocardiography, 
angiography), therapeutics details (e.g., medications, coronary stenting, cardiopulmonary 
resuscitation), in-hospital events, discharge status/diagnosis, and follow-up events.
Intervention
To develop our intervention, we followed recommendations from the Medical Research 
Council guidelines for complex interventions.(15) Starting in 2011, we performed in-depth 
interviews and focus groups among participating clinicians (cardiologists and internists) and 
nurses to identify facilitators, barriers, and context to optimal in-hospital acute coronary 
syndrome care to create a theoretical model for improving care. We supplemented these 
qualitative data with data from systematic reviews evaluating the effects of components of 
typical quality improvement interventions, including audit and feedback(16) and checklists.
(17) Based on data from previous systematic reviews, audit and feedback reports, which 
were generated by our electronic data capture system, were electronically delivered monthly 
and were linked to monthly quality improvement team meetings with standardized agendas 
using the Plan-Do-Study-Act change cycle to guide change management. To help prepare 
quality improvement teams, we provided free quality improvement training through the 
Institute for Healthcare Improvement’s Open School online training program (www.ihi.org/
education/ihiopenschool).
We added tools for improving health behaviors, including: 1) tobacco cessation materials 
and training developed by Quit Tobacco International that have been demonstrated to be 
effective for tobacco cessation among patients with diabetes in India;(18) 2) pamphlets for 
recommendations on health diets, lifestyle, and physical activity developed for a post-
myocardial infarction yoga intervention in India (CTRI/2012/02/002408); and 3) 
recommendations for home-based cardiac rehabilitation given the lack of facility-based 
cardiac rehabilitation programs in Kerala. We also provided contact information on 
American Heart Association emergency cardiovascular care training centers in Kerala for the 
development of in-hospital cardiac arrest (code) or rapid response teams for hospitals that 
did not have these teams in place.
The comparator group was provided with no special instruction in the care of their patients 
and was considered to be “usual care” according to local standards.
Outcomes
Our primary outcome was the composite measure of major adverse cardiovascular events at 
30 days post-discharge. Sites’ local staff, supervised by the site principal investigator, 
adjudicated outcomes independently during index hospitalization or during in-person clinic 
or telephonic follow-up based on clinical decision-making and trial criteria and reported 
these outcomes centrally using electronic case report forms. When participants died during 
the 30-day follow-up period, then the events were reported by next of kin. While central, 
blinded adjudication is generally preferred, the potential bias is limited in the case of 
objective outcomes based on a 2008 meta-epidemiological analysis of 314 non-blinded 
versus 432 blinded trials (Odds Ratio = 1.01 [95% CI: 0.92 to 1.10]) for non-blinded trials 
being more likely to demonstrate a beneficial effect.(19) Further, central adjudication was 
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not feasible based on the resources available and thus we made the pragmatic decision to 
rely upon site staff for outcome assessment.
We defined major adverse cardiovascular event as any one of the following: death, recurrent 
infarction, stroke, or major bleeding defined by the Global Utilization of Streptokinase and 
Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO) trial, which is 
defined by intracerebral hemorrhage or bleeding resulting in substantial hemodynamic 
compromise requiring treatment.(20) We chose this definition over others because it was the 
easiest for clinicians to use for outcome assessment.
Our secondary outcomes included: 1) in-hospital and discharge medication prescription 
rates, 2) discharge advice regarding healthy lifestyles (diet, physical activity, and tobacco 
cessation), 3) in-hospital and 30-day expanded major adverse cardiovascular events, which 
we defined as our primary outcome plus urgent revascularization or other reported 
cardiovascular events.
We also performed sub-studies of ACS QUIK by collecting data on health-related quality of 
life and individual- and household-level (or microeconomic) costs at 30-day follow-up using 
a previously published instrument(21) developed in conjunction with experts from the World 
Bank given the dearth of data for these patient-centered outcomes in India. For health-
related quality of life, we used a version of the Seattle Angina Questionnaire that was 
translated into Malayalam, the local language, for self-administration. For evaluation of 
microeconomic costs, we used our previously published, interviewer-administered 
instrument developed to capture direct and indirect costs associated with cardiovascular 
disease hospitalization.(21) Our previous microeconomic survey had been performed prior 
to the implementation of a national government insurance program for families below the 
poverty line.
Sample size
To estimate our sample size, we used data from the Kerala Acute Coronary Syndrome 
Registry to extrapolate a baseline major adverse cardiovascular event rate for patients with 
myocardial infarction at 30 days (10.4%). We used these same data to estimate intra-class 
correlation coefficient for the primary outcome (in-hospital major adverse cardiovascular 
event, ICC = 0.05). We then used data from the CRUSADE Registry to estimate an effect 
size by using the differences in in-hospital mortality rate between highest and lowest 
performing centers (4.2% vs. 6.3%, respectively).(6)
We sought input from experts in stepped wedge trial design methodology(22) who created a 
menu-driven program for sample size estimation of cluster randomized stepped wedge trials 
in Stata (StataCorp LP, College Station, TX).(23) We further applied the stepped wedge 
design effect and increased our sample size to account for a 5% lost-to-follow-up rate to 
arrive at a total sample size of 15,750 participants, which would provide 80% power with a 
significance level of 0.05 to detect a 2.4% reduction of 30-day major adverse cardiovascular 
event rate by the intervention from the anticipated 10.4% by the local standard care.
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Randomization, Allocation Concealment, and Blinding
We performed randomization centrally using a computer-generated, random number 
sequence that was only known by the 2 biostasticians on our team (DK, LZ). We stratified 
our randomization by hospital size to minimize imbalances throughout the trial. Three weeks 
prior to each step, we identified which hospitals were randomly selected to move from the 
comparator group to the intervention group for that step so that we could plan for site-level 
training on the quality improvement intervention. We did not announce which hospitals were 
selected at each step to other hospitals outside of their cohort; however, because of the 
nature of the study, formal blinding was not feasible.
Data collection and management
Data collection occurred at each participating site through a customized electronic data 
capture system with in-built limits to minimize data entry errors (Data Template, Bangalore, 
India). The data capture system was specifically built to provide audit and feedback reports 
as part of the quality improvement intervention. Data cleaning was a systematic, semi-
automated process led by 1 research coordinator, 1 data manager, 1 biostatistician, and 3 
zonal project coordinators in conjunction with the site investigators, and staff. Data queries 
were performed biweekly and sent to sites for data verification or correction.
Statistical analyses
All participants who were screened and invited to participate in this trial will be accounted 
for, in accordance with the CONSORT statement for reporting trials of non-pharmacologic 
interventions.(24) Reasons for early withdrawal will be listed for all clusters that 
prematurely discontinued the study. Baseline demographic variables, such as age, sex, and 
relevant clinical variables will be summarized for each group. Summaries of continuous 
baseline variables will be presented as means and standard deviations together with medians 
and minimum and maximum values. Categorical variables will be described as frequencies 
and percentage.
The analysis will be performed using the intention to treat principle (i.e., all patients 
recorded in the data base during the 24 month period will be included and considered 
exposed to the intervention or unexposed according to the randomization schedule regardless 
of when the intervention was actually implemented). For the primary outcome analysis, 30-
day major adverse cardiovascular event rates will be modeled using mixed effects logistic 
regression with random cluster (hospital) effects as well as a fixed time effect every 4 
months. Baseline data collected from the first time period will be tabulated by order of 
implementation, 12 to 13 clusters in 5 groups. The adequacy of randomization will be 
examined and we will include any hospital level variable unbalanced at baseline in the 
model as a sensitivity analysis. The patient level covariates included will be derived from the 
previously validated Global Registry of Acute Coronary Events (GRACE) risk score.(25) In 
the unlikely event that patient-level GRACE risk score covariates are not balanced between 
two groups, we will perform a sensitivity analysis by adjusting for those factors.
Subgroup analyses—The following a priori sub-group analyses will be carried out to 
evaluate potential heterogeneity of effect.
Huffman et al. Page 6
Am Heart J. Author manuscript; available in PMC 2018 March 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Site level characteristics
• Hospital size
• Use of quality improvement toolkit components
Participant level characteristics
• Age (<65 years and ≥65 years)
• Sex
• ST-segment elevation myocardial infarction vs. non-ST-segment elevation 
myocardial infarction
The results of these subgroup analyses will be treated with caution because this study was 
not powered for these analyses.
Interim analysis—To adjust for one interim analysis at 12 months, the O’Brien Fleming 
stopping boundary for the interim analysis was set to z = 2.797, p-value 0.005 and for the 
final analysis to z = 1.977, p-value 0.048.
Missing data—If the data are “not obtained” on the 30-day follow-up assessment form 
following the outpatient department follow-up visit, three telephone call attempts, response 
from mailed postcard, or home visits in limited circumstances by the site coordinator, then 
data will be considered as missing. We will perform sensitivity analyses using multiple 
imputation to evaluate the potential effect of missing outcomes.
Monitoring
We performed risk-based central statistical monitoring to evaluate sites’ performance and to 
direct risk-based, in-person, site monitoring visits. Our central statistical monitoring was 
largely based on freely available statistical tools developed by Kirkwood and colleagues(26) 
to evaluate the presence of outliers, inliers, and correlation among covariates associated with 
the outcome (major adverse cardiovascular events), particularly covariates part of the 
GRACE risk score,(25) namely age, systolic blood pressure, heart rate, and creatinine.(5) 
We also included covariates related to hospital size and previous trial participation.
Process evaluation
We applied methods of process evaluation as outlined by guidance documents from the 
Medical Research Council for process evaluation of complex interventions.(27) We asked 
site investigators about their use of the quality improvement intervention components 
approximately 4 to 8 months after crossover to the intervention group through online 
surveys. We supplemented these surveys with in-depth interviews to evaluate context, 
implementation fidelity, dose, reach, mechanisms of effect, and sustainability.
Ethics
Informed consent was obtained per guidelines for ethical research in human subjects. Ethical 
oversight was provided by the Institutional Ethics Committee (IEC) of participating 
hospitals. In instances where hospitals did not have an IEC, then hospitals deferred to the 
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Cardiological Society of India – Kerala chapter ethics committee, which evaluated and 
approved the protocol. The Northwestern University Institutional Review Board and Centre 
for Chronic Disease Control (ACS QUIK national coordinating center) IEC also evaluated 
and approved the protocol for this trial. The trial also received approval from the Indian 
Council for Medical Research’s Health Ministry Screening Committee.
Results
Of the hospitals participating, 84% are private or non-profit, and 16% are public, 
government hospitals. Participant recruitment through September 2016 is 33% above target 
recruitment, and 30-day follow-up has reached 96.5%. In absolute numbers, we have 
recruited 19,524 participants, of whom 76% are men and 63% have ST-segment elevation 
myocardial infarction.
Discussion
ACS QUIK aims to evaluate the effect of a quality improvement intervention on process of 
care measures and clinical outcomes among >15,000 patients with ACS across 63 hospitals 
in Kerala, India using a cluster randomized stepped wedge trial design. To our knowledge, 
this study is only the second cluster randomized stepped wedge myocardial infarction 
quality improvement program (Clinical Pathways in Acute Coronary Syndrome – 3(9) being 
the other such trial) and the first of its kind in India. The stepped wedge trial design was 
employed because of several important features.(22) First, this design has stronger causal 
inference in evaluating the potential effects of an intervention compared with a pre/post or 
even interrupted time series study design, which can be influenced by secular trends. This 
point is particularly relevant in Kerala where the cardiovascular health care system is 
changing rapidly. Second, the design allows for sequential implementation of the 
intervention across all (63 by the end of the trial in this case) sites. The mean period of time 
that hospitals spend in the intervention period is 12 months (range 4 to 20 months). Third, 
the stepped wedge design allows all hospitals to eventually receive the intervention, which is 
important when the intervention is deemed likely to be beneficial. This design helps avoid 
potential ethical concerns about sites being randomized to the control arm of a trial 
throughout the entire study period.
However, the stepped wedge design also includes important limitations. First, because all 
hospitals need to begin the trial at the same time, trial initiation can only begin when all sites 
are ready. This can lead to unexpected delays. Second, if the trial is below target recruitment, 
then the trial cannot be extended without causing imbalance between the intervention and 
control groups because the period of extension occurs only after all groups have crossed over 
to the intervention period. Third, if the trial is ahead of target recruitment, then the trial 
cannot be stopped early for similar reasons of imbalance between the intervention and 
control groups. Therefore, investigators will need to raise additional funds to cover these 
additional recruitment costs. Sponsors and expert groups should be aware of these 
limitations when calling for similar stepped wedge trials.(28)
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ACS QUIK aims to use a cluster randomized stepped wedge clinical trial design to 
implement and evaluate a locally developed quality improvement intervention to improve 
myocardial infarction process of care and clinical outcomes in Kerala. If successful in 
achieving its primary outcome, then this trial will provide high quality evidence for 
implementation of this intervention more broadly throughout India and potentially other 
low- and middle-income countries. Quality improvement is more likely to succeed in the 
context of longitudinal stakeholder buy-in at multiple levels, including individual, 
institutional, and organizational;(29,30) we have found the Cardiological Society of India – 
Kerala chapter to be a vital partner in this research. Whether or not this intervention would 
be suitable for other acute cardiovascular conditions (e.g., stroke, acute heart failure) 
remains uncertain but is of interest to our team. Data from our ongoing process evaluation 
will be important to understand what site- and personnel-level factors are necessary for 
successful implementation of this intervention. Our team is also exploring funding models 
(e.g., subscription-based model, partnership model) and automation of data management, 
cleaning, and monitoring not only to maintain financial support for these activities but also 
to minimize costs to achieve long-term sustainability.
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Figure 1. 
Stepped wedge trial design schema. The white boxes represent periods of usual care, and the 
black boxes represent periods of intervention where by hospitals receive and implement the 
quality improvement intervention. By design, all hospitals start in the usual care, or control, 
arm and all end up in the intervention arm but the timing, or step, when hospitals move from 
control to intervention is random.
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